CTLA4 and cancer: Similarly, immunotherapies like pembrolizumab and nivolumab, which target programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways, have shown promise in attacking cancer cells by unleashing the immune system, but their effectiveness varies among patients [55].